MLYS
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) Stock News
The latest MLYS headlines and market coverage — 1 recent story, updated throughout the day.
- The Motley Fool·
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in Q1 2026, valued at approximately $4.11 million, reducing its stake to 11,000 shares. Despite the fund's reduction, Mineralys stock has surged 87.84% over the past year. The clinical-stage biotech company is awaiting FDA approval for its lead candidate lorundrostat by December 22, 2026, and maintains $646 million in cash.